RUNNING CYCLES: LENGTH, BREAKS, AND RESETS

1.GH secretagogues: desensitization and why breaks matter

GHRP receptors (specifically the ghrelin receptor, GHSR1a) desensitize with continuous, repetitive stimulation. Running a GHRP daily for 4+ months without a break produces measurably declining GH pulses over time. The pituitary's somatotroph cells become less responsive to the signal, and the receptor count at the cell surface downregulates. The result: the same dose that was working at week 4 produces noticeably less effect at week 16.

The practical cycle structure for GHRPs: 12-16 weeks on, followed by 4-8 weeks off. The off period allows receptor upregulation and sensitivity restoration. When you return to the compound after a proper break, effectiveness is restored to near-baseline levels. Users who run GHRPs continuously for 6+ months without breaks frequently report their protocol stopped working by month 3-4.

CJC-1295 no DAC (Mod GRF 1-29) desensitizes less than the GHRPs because it mimics the natural GHRH signal in a pulsatile way rather than providing constant receptor stimulation. This means the GHRH component of a combination protocol is less dependent on cycling than the GHRP component. However, running any GH secretagogue continuously still warrants a periodic break to allow full physiological reset.

Ipamorelin is the GHRP with the most selective action and the most favorable desensitization profile. Some users run ipamorelin at moderate doses (200-300 mcg before sleep) for 5-6 months with only a 2-4 week break. This is less aggressive than running GHRP-2 or GHRP-6 and may be viable for some individuals, though receptor sensitivity data is more robust in animal models than in long-term human studies.

The off-cycle period is not wasted time. GH pulse patterns naturally recover and often overshoot slightly above baseline during the off period. Some users report improved sleep and mood during off periods as the body recalibrates its own GH release patterns without exogenous signal augmentation.

Bloodwork helps quantify cycle status. IGF-1 measured at week 8-10 of an active cycle should be elevated from baseline. IGF-1 measured at week 16 of the same cycle showing the same or lower values than week 8 is evidence of desensitization and a signal that a break is warranted.

2.BPC-157: injury-focused vs. continuous maintenance

For injury-specific use, the protocol structure is goal-oriented rather than cycle-length oriented. Run BPC-157 for 10-12 weeks. At week 12, assess the injury: resolved, substantially improved, partially improved, or unchanged. If resolved or substantially improved, discontinue. If improved but not complete, consider a 4-week break and reassess before deciding on another cycle.

BPC-157 does not appear to produce receptor desensitization the way GHRPs do. Animal studies have not identified meaningful tolerance development, and human user experience generally does not reflect diminishing returns over the timeframe of a typical 12-week cycle. The primary rationale for taking a break is practical rather than pharmacological — giving the body time to consolidate the healing response and to assess what was accomplished before committing to another cycle.

For continuous use applications — gut health maintenance, systemic anti-inflammatory support in high-training athletes, or general healing optimization — some users run BPC-157 on a 12 weeks on / 4 weeks off cycle indefinitely. Long-term animal safety data is reassuring: no significant toxicity has been observed even at extended high doses in rodent models. Human long-term safety data is limited but consistent with the animal findings.

A lower maintenance dose (125-250 mcg daily or even every other day) is sometimes used after an initial higher-dose induction phase (500 mcg daily for weeks 1-4). This reduces cost while maintaining the systemic healing and anti-inflammatory benefits. Whether the maintenance dose is equivalent to the induction dose for ongoing protection is not firmly established in the literature.

The most important cycle consideration for BPC-157: don't stop too early because you don't feel immediately better. For chronic injuries (those present for months to years), the healing timeline is longer. Stopping at week 6 because improvement has not been dramatic enough misses the bulk of the remodeling phase, which typically produces the most meaningful structural improvement in weeks 8-12.

3.GLP-1 agonists: continuous protocols and exit strategies

GLP-1 agonists are not cycled the way performance peptides are. The clinical protocol — and the pattern that produces the best outcomes in practice — is continuous weekly administration. Weight regain after stopping is one of the most well-documented findings in obesity medicine: participants in the STEP and SURMOUNT trials regained a majority of lost weight within 12 months of stopping the drug.

The biological reason: GLP-1 receptors are tonically active in the brain's appetite regulation circuits. When you remove the exogenous agonist, hunger signals return to pre-treatment levels. For many users, this means the hunger that was suppressed for months returns — and body weight trends back toward the original setpoint.

The practical implication is that GLP-1 agonists are more lifestyle medications than interventions with a defined endpoint. The sustainable long-term approach: titrate to the lowest effective maintenance dose after reaching goal weight, rather than stopping entirely. Many users maintain on 0.25 mg semaglutide weekly (half the starting dose) indefinitely and maintain their weight loss.

If stopping is the goal, the most successful exit strategies involve gradually tapering dose while simultaneously building robust eating behavior changes and maintaining resistance training. The purpose is to establish new behavioral patterns during the period of pharmacological appetite support that can persist when the drug is removed. Cold-turkey cessation typically results in faster and more complete weight regain than a structured taper and transition plan.

Switching compounds within the GLP-1 class can restart weight loss that has plateaued. Many users who plateau on semaglutide have achieved additional weight loss by switching to tirzepatide (the dual GLP-1/GIP mechanism). Those who plateau on tirzepatide may find retatrutide provides further effect. This class has a progression pathway for treatment-resistant cases.

4.Reading the signs: when to stop or adjust

For GH peptides: the clearest signs that a cycle has run its course or that a break is needed include: sleep quality improvement has stopped progressing (or even regressed), body composition changes have plateaued for 4+ weeks despite consistent protocol adherence, water retention has become excessive (indicating high-normal or above-normal IGF-1 that is causing more side effects than benefit), or blood test IGF-1 is not elevated from baseline despite 8+ weeks of use (suggesting the product is not working or the protocol timing is incorrect).

For BPC-157: stop the current cycle if the target injury has fully resolved (success). Pause and reassess if 12 weeks of use have produced no measurable improvement in the injury — injury type may not respond to this mechanism, or confounding factors may need addressing. Reduce dose or adjust site if injection-site related issues are developing.

For GLP-1 agonists: pause or reduce dose if GI side effects are severe after 4 weeks at a given dose (the adaptation window has passed — further increase is unlikely to help at that dose level). Stop immediately and seek evaluation if you develop severe abdominal pain radiating to the back, persistent vomiting, or signs of an allergic reaction.

Universal signal to stop any protocol: a new medical diagnosis, new medication, pregnancy, or significant health event. Peptide protocols are discretionary health interventions — they are not worth continuing through situations where the risk-benefit calculus changes substantially.

The most common mistake is stopping too early because of unrealistic timeline expectations, and the second most common is continuing too long because the user is reluctant to stop something they are invested in. Objective logging — weekly weight, monthly measurements, periodic bloodwork — provides the data to make these decisions rationally rather than emotionally.